Published in Rev Urol on January 01, 2002
Green tea catechins suppress the DNA synthesis marker MCM7 in the TRAMP model of prostate cancer. Mol Oncol (2007) 0.97
Strategies for prostate cancer prevention: Review of the literature. Indian J Urol (2008) 0.77
The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med (1994) 16.96
Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol (2002) 8.73
Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer (1975) 7.20
Variations in mortality by weight among 750,000 men and women. J Chronic Dis (1979) 5.57
Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst (1998) 4.72
Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst (1968) 4.68
International trends and patterns of prostate cancer incidence and mortality. Int J Cancer (2000) 3.73
Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst (1995) 3.24
Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst (1998) 2.97
Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst (2000) 2.77
Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res (1999) 2.30
A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res (1989) 2.18
Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer (1992) 1.96
Carotenoid content of fruits and vegetables: an evaluation of analytic data. J Am Diet Assoc (1993) 1.74
Dietary fat and prostate cancer: current status. J Natl Cancer Inst (1999) 1.61
Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev (1999) 1.56
The epidemiology of prostate cancer in Jamaica. J Urol (1998) 1.53
Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab (2000) 1.49
Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States) Cancer Causes Control (1998) 1.32
Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett (1998) 1.32
Cancer and insulin-like growth factor-I. A potential mechanism linking the environment with cancer risk. BMJ (2000) 1.26
Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep (2000) 1.25
Energy, nutrient intake and prostate cancer risk: a population-based case-control study in Sweden. Int J Cancer (1996) 1.24
Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2000) 1.24
Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol (1995) 1.21
Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology (1994) 1.15
Insulin-like growth factor-I and binding protein-3 and risk of cancer. Horm Res (1999) 1.11
Serologic precursors of cancer. Retinol, carotenoids, and tocopherol and risk of prostate cancer. J Natl Cancer Inst (1990) 1.05
Chemoprevention of prostate cancer: concepts and strategies. Eur Urol (1999) 1.04
A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer (1998) 1.03
Chemoprevention. CA Cancer J Clin (1995) 1.02
Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study. Int J Cancer (1996) 1.01
The effect of finasteride on prostate specific antigen: review of available data. J Urol (1996) 1.01
Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro. Urology (1995) 0.98
Inhibitory effects of selenium on the growth of DU-145 human prostate carcinoma cells in vitro. Biochem Biophys Res Commun (1985) 0.98
Cancer chemoprevention. J Clin Oncol (1994) 0.98
Body mass and prostatic cancer: a prospective study. BMJ (1988) 0.96
Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial. Prostate (1997) 0.94
Food-consumption trends between adolescent and adult years and subsequent risk of prostate cancer. Am J Clin Nutr (1990) 0.93
The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. Br J Cancer (1998) 0.92
Chemoprevention of prostate cancer: guidelines for possible intervention strategies. J Cell Biochem Suppl (1992) 0.91
Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents. J Clin Pathol (1999) 0.91
Dietary and hormonal evaluation of men at different risks for prostate cancer: plasma and fecal hormone-nutrient interrelationships. Am J Clin Nutr (1990) 0.91
Vitamin D and prostate cancer. Proc Soc Exp Biol Med (1999) 0.90
Tomatoes, lycopene, and prostate cancer. Proc Soc Exp Biol Med (1998) 0.89
Hormones and diet: low insulin-like growth factor-I but normal bioavailable androgens in vegan men. Br J Cancer (2000) 0.88
Chemoprevention of prostate cancer. Semin Urol (1995) 0.87
Prostate Cancer Prevention Trial (PCPT) update. Eur Urol (1999) 0.86
Clinical review: 67: Approach to chemoprevention of prostate cancer. J Clin Endocrinol Metab (1995) 0.86
Inhibition of the activity of 'basic' 5 alpha-reductase (type 1) detected in DU 145 cells and expressed in insect cells. J Steroid Biochem Mol Biol (1994) 0.85
Insulin-like growth factors and cancer. J La State Med Soc (1999) 0.84
Free fatty acid concentrations correlated with the available fraction of estradiol in human plasma. Cancer Res (1986) 0.83
Experimental basis for cancer prevention by vitamin E. Cancer Invest (2000) 0.83
Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma. Prostate (1997) 0.82
Cancer chemoprevention. J Natl Cancer Inst Monogr (1995) 0.81
Inhibition of rat prostate carcinogenesis by a 5alpha-reductase inhibitor, FK143. J Natl Cancer Inst (1997) 0.81
Immunohistochemical expression of pi class glutathione S-transferase in the basal cell layer of benign prostate tissue following chronic treatment with finasteride. J Clin Pathol (1999) 0.80
The role of diet in prostate cancer. Nutr Cancer (1987) 0.80
Cancer chemoprevention. Part 2: Hormones, nonclassic antioxidant natural agents, NSAIDs, and other agents. Oncology (Williston Park) (1998) 0.79
Role of diet in cancer incidence in Hawaii. Cancer Res (1983) 0.77
Re: Tomatoes, tomato-based products, lycopene, and prostate cancer: review of the epidemiologic literature. J Natl Cancer Inst (1999) 0.77
Effect of early treatment of prostate cancer with the 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats. Prostate (1998) 0.77
Selenium and risk of prostate cancer. Lancet (1998) 0.77
Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex. J Natl Cancer Inst (1995) 0.76
Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group. Urology (1997) 0.76
Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78
Benefits and harms of CT screening for lung cancer: a systematic review. JAMA (2012) 8.71
Are racial and ethnic minorities less willing to participate in health research? PLoS Med (2005) 7.88
Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin (2010) 4.76
Survival of blacks and whites after a cancer diagnosis. JAMA (2002) 4.27
Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin (2009) 3.25
Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat (2002) 3.19
American Cancer Society lung cancer screening guidelines. CA Cancer J Clin (2013) 3.16
Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat (2008) 2.97
Cancer screening in the United States, 2011: A review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin (2011) 2.76
American society of clinical oncology policy statement: disparities in cancer care. J Clin Oncol (2009) 2.12
Low-dose spiral CT screening and evaluation of the solitary pulmonary nodule. Oncology (Williston Park) (2014) 2.06
Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening. CA Cancer J Clin (2015) 1.97
Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin (2014) 1.95
The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol (2008) 1.93
Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin (2013) 1.75
Palliative care and the quality of life. J Clin Oncol (2011) 1.75
Disaggregating the effects of race and poverty on breast cancer outcomes. J Natl Cancer Inst (2002) 1.44
High prevalence of triple-negative tumors in an urban cancer center. Cancer (2008) 1.43
Effects of untreated syphilis in the negro male, 1932 to 1972: a closure comes to the Tuskegee study, 2004. Urology (2005) 1.42
Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer (2010) 1.38
Effects of an outreach and internal navigation program on breast cancer diagnosis in an urban cancer center with a large African-American population. Cancer (2008) 1.36
Age and grade trends in prostate cancer (1974-2003): a Surveillance, Epidemiology, and End Results Registry analysis. Am J Clin Oncol (2008) 1.28
Extensive inguinal lymphadenectomy improves overall 5-year survival in penile cancer patients: results from the Surveillance, Epidemiology, and End Results program. Cancer (2010) 1.28
Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States. Cancer Epidemiol Biomarkers Prev (2012) 1.14
Racial disparities in colorectal cancer. Curr Probl Cancer (2007) 1.11
From the guest editors: introduction for the impact of health care reform on cancer patients. Cancer J (2010) 1.08
Colorectal carcinoma in black and white race. Cancer Metastasis Rev (2003) 1.07
Prostate cancer: current evidence weighs against population screening. CA Cancer J Clin (2009) 1.05
Prostate cancer in black and white Americans. Cancer Metastasis Rev (2003) 1.05
Myeloma and race: a review of the literature. Cancer Metastasis Rev (2003) 1.00
The globalization of tobacco use: 21 challenges for the 21st century. CA Cancer J Clin (2010) 1.00
Disparities in medical care among commercially insured patients with newly diagnosed breast cancer: opportunities for intervention. Cancer (2010) 0.99
Introducing the 2010 American Cancer Society prostate cancer screening guideline. CA Cancer J Clin (2010) 0.99
Risk-based mammography screening: an effort to maximize the benefits and minimize the harms. Ann Intern Med (2012) 0.98
The study of accrual to clinical trials: can we learn from studying who enters our studies? J Clin Oncol (2004) 0.97
Is race really a negative prognostic factor for cancer? J Natl Cancer Inst (2009) 0.97
Racial disparities in lung cancer. Curr Probl Cancer (2007) 0.96
NIH consensus development statement on hydroxyurea treatment for sickle cell disease. NIH Consens State Sci Statements (2008) 0.95
Examining racial differences in diffuse large B-cell lymphoma presentation and survival. Leuk Lymphoma (2013) 0.95
A black-white comparison of the quality of stage-specific colon cancer treatment. Cancer (2010) 0.93
Characteristics and treatment modalities for African American women diagnosed with stage III breast cancer. Cancer (2009) 0.90
Avoidable cancer deaths globally. CA Cancer J Clin (2011) 0.90
Taking action to ease suffering: advancing cancer pain control as a health care priority. CA Cancer J Clin (2009) 0.89
Some perspective on black-white cancer statistics. CA Cancer J Clin (2002) 0.89
Obesity-driven inflammation and cancer risk: role of myeloid derived suppressor cells and alternately activated macrophages. Am J Cancer Res (2013) 0.89
Racial differences in the incidence and outcomes for patients with hematological malignancies. Curr Probl Cancer (2007) 0.88
Informed consent for prostate-specific antigen-based screening. Urology (2003) 0.84
A research agenda for radiation oncology: results of the radiation oncology institute's comprehensive research needs assessment. Int J Radiat Oncol Biol Phys (2012) 0.84
Health care policy and cancer survivorship. Cancer (2013) 0.82
Lung cancer and race: equal treatment yields equal outcome among equal patients, but there is no equal treatment. J Clin Oncol (2005) 0.82
CDC Grand Rounds: the future of cancer screening. MMWR Morb Mortal Wkly Rep (2015) 0.82
Peak window of suicides occurs within the first month of diagnosis: implications for clinical oncology. Psychooncology (2011) 0.81
Prostate cancer screening; is this a teachable moment? J Natl Cancer Inst (2009) 0.81
The National Breast and Cervical Cancer Early Detection Program: toward a system of cancer screening in the United States. Cancer (2014) 0.80
Phase III prostate cancer chemoprevention trials. Recent Results Cancer Res (2014) 0.75
Oophorectomy in carriers of BRCA mutations. N Engl J Med (2002) 0.75
A brief history of the American Cancer Society Extramural Research Program. CA Cancer J Clin (2012) 0.75
Chemoprevention in prostate cancer. Curr Probl Cancer (2004) 0.75
Reviewer acknowledgment 2015. CA Cancer J Clin (2015) 0.75
Information over exaggeration. US News World Rep (2009) 0.75
The argument for breast cancer screening. Clin Adv Hematol Oncol (2014) 0.75
Curbing tobacco's toll starts with the professionals: World No Tobacco Day. Lancet (2005) 0.75
New ACS chief medical officer. Interview by Carrie Printz. Cancer (2008) 0.75